Kymera Therapeutics appoints Karen Weisbach as VP, people and culture » 07:1807/2907/29/21
Kymera Therapeutics (KYMR) announced the appointments of Karen Weisbach, as Vice President, People and Culture, and Jolly Bhatia as Vice President, Quality. Prior to Kymera, she served in human resource leadership roles at bluebird bio (BLUE), including building and leading the global People Partner function responsible for driving talent and organizational strategies with an emphasis on employee engagement, development, and performance. Prior to Kymera, Bhatia served in quality leadership roles at X4 Pharmaceuticals, Inc., Alnylam Pharmaceuticals, Inc., and Genzyme Corporation.
|Over a week ago|
Fly Insider: Fast Acquisition, Airbnb among weeks notable trades » 14:1807/1207/12/21
KYMR, FST, CERE, HCHC, GOOG, FB, CVNA, ABNB
Welcome to "Fly Insider,"…
Kymera Therapeutics presents new preclinical data on STAT3 degraders » 08:2107/1207/12/21
Kymera Therapeutics announced new preclinical data demonstrating the therapeutic potential of its STAT3 degraders for the treatment of peripheral T-cell lymphoma with aberrant STAT3 activation. Kymera's STAT3 degraders have been shown to strongly repress cancer cell growth in preclinical models of STAT3-dependent heme malignancies, including subtypes of PTCL such as ALK-positive anaplastic large cell lymphoma. Kymera's lead STAT3 degrader candidate, KT-333, is currently in preclinical development and Kymera plans to submit an Investigational New Drug Application to the U.S. Food and Drug Administration in the fourth quarter of 2021 and, if cleared, initiate a Phase 1 clinical trial in patients thereafter. Data highlights include: Kymera has discovered a series of potent and selective STAT3 degraders with activity against both wild-type and clinically-relevant mutant forms of STAT3. STAT3 degraders result in growth arrest and increased cell death of ALK-positive ALCL, as well as STAT3-mutant NK/T-cell lymphoma and ALK-negative ALCL cell lines, both in vitro and in vivo, including complete tumor regressions in vivo in ALK-positive ALCL with IV weekly dosing. Pathway analyses in STAT3 degrader-treated ALK-positive ALCL show down-regulation of STAT3-regulated processes including cytokine responses and consistent down-regulation of cell cycle signatures and up-regulation of immune pathways, suggesting modulation of tumor cell-intrinsic processes and the potential to regulate cell-cell interactions in the tumor microenvironment. A subset of transcriptional responses to STAT3 degrader is conserved between ALK-positive ALCL and STAT3 mutant NK/T-cell lymphoma cell lines.
Kymera data 'fundamentally de-risks' approach, says Piper Sandler » 04:5307/0707/07/21
Piper Sandler analyst…
Piper Sandler analyst Edward Tenthoff reiterates an Overweight rating on Kymera Therapeutics with an $80 price target after the company last week reported first-ever human data on IRAK4 degrader KT-474. The analyst believes this "safe, potent IRAK4 knock-down fundamentally de-risks" Kymera's protein degradation approach. The analyst adds that the company strengthened its balance sheet through a secondary offering.
|Over a month ago|
Kymera Therapeutics 4.755M share Secondary priced at $47.00 » 06:0607/0107/01/21
The deal size was…
The deal size was increased to 4.755M shares from 4.0M. Morgan Stanley, JPMorgan, Cowen and Guggenheim are acting as joint book running managers for the offering.
Kymera Therapeutics files to sell 4M shares of common stock » 16:3306/2806/28/21
Managers include Morgan…
Managers include Morgan Stanley, J.P. Morgan, Cowen, and Guggenheim Securities.
Kymera Therapeutics reports 'positive' results from Phase 1 trial of KT-474 » 06:0706/2806/28/21
Kymera Therapeutics announced positive interim results from the Single Ascending Dose portion of the Phase 1 clinical trial of KT-474, demonstrating the first degrader proof-of-mechanism in targeted protein degradation in a randomized, placebo-controlled healthy volunteer study. KT-474 has achieved and exceeded the Phase 1 target degradation of 85% within the SAD portion of the Phase 1 trial dosed to date, with profound IRAK4 degradation after a single oral dose that lasted for at least six days at all dose levels. The partial clinical hold on the Multiple Ascending Dose portion of the Phase 1 trial of KT-474 has been lifted following review by the U.S. FDA of interim safety, pharmacokinetic and pharmacodynamic data from the first three cohorts of the SAD healthy volunteer portion of the Phase 1 study. In the SAD portion of the trial, healthy volunteer subjects are randomized 6:2 to either a single oral dose of KT-474 or placebo. Interim data, which also include results from the fourth cohort of the trial, showed dose and time-dependent IRAK4 degradation following single oral KT-474 dose administration. IRAK4 levels were measured in peripheral blood mononuclear cells (PBMC) using mass spectrometry. Following a single KT-474 oral dose, IRAK4 reduction was observed as early as eight hours post-dose, reached maximal reduction at 48 to 72 hours, and was sustained for at least six days with subsequent recovery towards pre-treatment baseline across all dose groups. In the fourth cohort, following a single 300 mg dose of KT-474, median IRAK4 reduction from baseline at 48 hours was 90% compared to a 16% increase in the placebo group, with maximum IRAK4 reduction of 94%, demonstrating proof-of-mechanism for KT-474. KT-474, to date, has demonstrated oral bioavailability, predictable and dose-dependent plasma exposures, and a half-life supportive of oral daily dosing. No treatment-related adverse events have been observed to date.
Kymera Therapeutics appoints Elaine Caughey as chief business officer » 16:0506/2106/21/21
Kymera Therapeutics announced the appointment of Elaine Caughey as chief business officer, or CBO. Caughey joins Kymera with over 20 years of experience in the biotechnology industry, including leadership roles in corporate development, business and commercial operations, new product strategy, and investing. Caughey joins Kymera with over 20 years of experience in the biotechnology industry. Prior to Kymera, she led business development, strategy and operations as the CBO at Cygnal Therapeutics.
Kymera presents data showing KT-413 active in models, says Piper Sandler » 13:4806/2106/21/21
Piper Sandler analyst…
Piper Sandler analyst Edward Tenthoff reiterated an Overweight rating and $80 price target on Kymera Therapeutics. Kymera presented preclinical data on IRAKIMiD degrader KT-413 at the virtual International Conference on Malignant Lymphoma meeting showing that KT-413 was active in MYD88-mutant mouse and DLBCL patient-derived models, and was additive to rituximab, ibrutinib and venetoclax, Tenthoff tells investors in a research note. Kymera intends to file an IND for KT-333 in solid tumors in 4Q21, the analyst adds.
Kymera Therapeutics presents preclinical data for KT-413 » 08:3806/2106/21/21
Kymera Therapeutics announced new preclinical data on its IRAKIMiD degrader KT-413's potential as both a monotherapy and in combination with other anticancer agents. The data were featured in an oral presentation at the 16th Annual International Conference on Malignant Lymphoma virtual meeting, taking place from June 18 - 22, 2021. IRAKIMiDs are novel heterobifunctional degraders designed to degrade both IRAK4 and IMiD substrates, including Ikaros and Aiolos, with a single small molecule. IRAKIMiDs synergistically target both the MYD88-NFkB and IRF4-Type 1 interferon pathways to enhance and broaden antitumor activity in MYD88-mutant diffuse large B-cell lymphoma. KT-413 is being developed initially for the treatment of relapsed/refractory MYD88-mutant DLBCL, with the potential to expand into other MYD88-mutant indications and IL-1R/NFkB-driven malignancies. KT-413 is currently in preclinical development and Kymera plans to submit an Investigational New Drug Application to the U.S. Food and Drug Administration in the second half of 2021 and, if cleared, initiate a Phase 1 clinical trial in patients thereafter. Data highlights include: In the OCI-Ly10 MYD88-mutant mouse xenograft model, intermittent dosing of KT-413 in vivo induced deep and sustained antitumor activity, including complete or partial regressions, that was superior to the clinically active IRAK4 kinase inhibitor CA-4948 or the latest generation IMiD CC-220. KT-413 showed strong tumor growth inhibition in multiple MYD88-mutant DLBCL patient-derived xenograft in vivo models. KT-413 showed strongly additive antitumor activity in combination with the anti-CD20 monoclonal antibody rituximab, the BTK inhibitor ibrutinib, or the BCL-2 inhibitor venetoclax, in MYD88-mutantOCI-Ly10 xenografts in vivo, suggesting the potential for therapeutically relevant drug combinations in MYD88-mutant DLBCL.